Pelage PP405-2001 Androgenetic Alopecia

We are currently recruiting adults ages 18 to 55 with adult pattern hair loss (androgenetic alopecia) to participate in a Phase 2 clinical trial. The main purpose of this study is to evaluate how safe and effective the investigational drug PP405 is in people experiencing hair loss from androgenetic alopecia. There will be no cost to you for being considered or for taking part in this study.

* Les questions avec un astérisque rouge sont obligatoires.

Commencer le questionnaire